Clinical experiment designed to assess clinical efficacy targeting CACNA1G/CLOCK/GABRA1 in human. Primary outcome: Correlation between objective sleep quality metrics (slow-wave sleep percentage, sleep efficiency) a
Description
Sleep Disruption and Alzheimer's Disease — mechanism and intervention
Background and Rationale
Sleep disturbances represent one of the earliest detectable biomarkers in Alzheimer's Disease (AD), often manifesting years before cognitive symptoms emerge. This longitudinal clinical study investigates the bidirectional relationship between sleep disruption and AD pathogenesis, examining how altered sleep architecture accelerates amyloid-beta accumulation and tau pathology while simultaneously being exacerbated by these neuropathological changes. The study employs a comprehensive approach combining objective sleep monitoring, neuroimaging, cerebrospinal fluid biomarkers, and cognitive assessments in cognitively normal older adults at risk for AD. Participants undergo baseline polysomnography to characterize sleep patterns, followed by PET imaging for amyloid and tau deposition, CSF sampling for AD biomarkers, and detailed neuropsychological testing....
Sleep Disruption and Alzheimer's Disease — mechanism and intervention
Background and Rationale
Sleep disturbances represent one of the earliest detectable biomarkers in Alzheimer's Disease (AD), often manifesting years before cognitive symptoms emerge. This longitudinal clinical study investigates the bidirectional relationship between sleep disruption and AD pathogenesis, examining how altered sleep architecture accelerates amyloid-beta accumulation and tau pathology while simultaneously being exacerbated by these neuropathological changes. The study employs a comprehensive approach combining objective sleep monitoring, neuroimaging, cerebrospinal fluid biomarkers, and cognitive assessments in cognitively normal older adults at risk for AD. Participants undergo baseline polysomnography to characterize sleep patterns, followed by PET imaging for amyloid and tau deposition, CSF sampling for AD biomarkers, and detailed neuropsychological testing. A subset of participants with significant sleep disruption will be randomized to receive targeted sleep interventions including cognitive behavioral therapy for insomnia (CBT-I), continuous positive airway pressure (CPAP) for sleep apnea, or pharmacological sleep enhancement. The intervention phase tests whether improving sleep quality can slow AD biomarker progression and preserve cognitive function. Key measurements include sleep efficiency, slow-wave sleep duration, amyloid-PET standardized uptake value ratios, CSF amyloid-beta 42/40 ratio, phosphorylated tau levels, and performance on sensitive cognitive measures. This study addresses a critical knowledge gap by establishing mechanistic links between sleep disruption and AD pathogenesis while testing therapeutic interventions. The innovation lies in its longitudinal design capturing the temporal relationship between sleep changes and biomarker evolution, potentially identifying sleep as a modifiable risk factor for AD prevention. Success would demonstrate that sleep disturbances causally contribute to AD pathology and that sleep interventions represent viable therapeutic strategies for at-risk individuals.
This experiment directly tests predictions arising from the following hypotheses:
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
Biorhythmic Interference via Controlled Sleep Oscillations
Experimental Protocol
Phase 1 (Months 1-6): Recruit 300 cognitively normal adults aged 60-75 with family history of AD or APOE4 carrier status. Conduct comprehensive baseline assessments including 3-night polysomnography, actigraphy for 2 weeks, amyloid-PET and tau-PET imaging, lumbar puncture for CSF biomarkers (Aβ42/40, p-tau181, p-tau217), and neuropsychological battery. Phase 2 (Months 7-12): Stratify participants by sleep disruption severity using sleep efficiency <85% and slow-wave sleep <15% as cutoffs. Randomize 150 participants with significant sleep disruption to intervention arms: CBT-I (n=50), CPAP therapy for those with AHI>15 (n=50), or low-dose trazodone 50mg (n=50). Control group (n=150) receives sleep hygiene education. Phase 3 (Months 13-24): Implement interventions with monthly compliance monitoring. Repeat polysomnography at 6 and 12 months post-intervention. Conduct interim CSF sampling at 12 months. Phase 4 (Months 25-36): Final comprehensive assessment battery identical to baseline. Primary endpoints include changes in amyloid-PET SUVR, CSF p-tau levels, and cognitive composite scores. Secondary measures include sleep architecture parameters, inflammatory markers (IL-6, TNF-α), and brain volume changes via MRI. Statistical analysis uses mixed-effects models controlling for age, APOE4 status, and baseline cognition, with 80% power to detect 20% reduction in biomarker progression.
Expected Outcomes
Participants with baseline sleep efficiency <80% will show 1.5-2.0 fold higher amyloid accumulation rates compared to good sleepers (SUVR increase >0.05 annually vs <0.03, p<0.01)
Sleep interventions will reduce CSF p-tau181 levels by 15-25% compared to controls over 24 months, with CBT-I showing superior efficacy (p<0.05)
Improved slow-wave sleep duration (>20% increase) will correlate with preserved cognitive performance on episodic memory tasks (r=0.4, p<0.001)
Sleep disruption severity at baseline will predict tau-PET accumulation in medial temporal lobe regions with effect size d=0.6-0.8
Intervention group will demonstrate 30% slower decline on cognitive composite scores compared to controls (Cohen's d=0.5)
CSF inflammatory markers will decrease by 20-30% in successful sleep intervention responders, mediating cognitive protection effects
Success Criteria
• Demonstrate statistically significant association between baseline sleep disruption and accelerated AD biomarker progression (amyloid or tau, p<0.01)
• Achieve ≥20% reduction in rate of biomarker accumulation in at least one intervention arm compared to controls
• Show dose-response relationship between sleep improvement magnitude and biomarker/cognitive outcomes (correlation r>0.3, p<0.05)
• Document intervention feasibility with ≥80% completion rate and ≥70% adherence to assigned treatments
• Identify sleep metrics that predict future cognitive decline with area under ROC curve >0.75
• Establish mechanistic pathway linking sleep disruption to AD pathology through inflammatory or clearance mechanisms with effect size d>0.4
TARGET GENE
CACNA1G/CLOCK/GABRA1
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Correlation between objective sleep quality metrics (slow-wave sleep percentage, sleep efficiency) and rate of CSF amyloid-beta accumulation over 18 months in cognitively normal older adults with family history of Alzheimer's disease.
Phase 1 (Months 1-6): Recruit 300 cognitively normal adults aged 60-75 with family history of AD or APOE4 carrier status. Conduct comprehensive baseline assessments including 3-night polysomnography, actigraphy for 2 weeks, amyloid-PET and tau-PET imaging, lumbar puncture for CSF biomarkers (Aβ42/40, p-tau181, p-tau217), and neuropsychological battery. Phase 2 (Months 7-12): Stratify participants by sleep disruption severity using sleep efficiency <85% and slow-wave sleep <15% as cutoffs. Randomize 150 participants with significant sleep disruption to intervention arms: CBT-I (n=50), CPAP therapy for those with AHI>15 (n=50), or low-dose trazodone 50mg (n=50). Control group (n=150) receives sleep hygiene education.
...
Phase 1 (Months 1-6): Recruit 300 cognitively normal adults aged 60-75 with family history of AD or APOE4 carrier status. Conduct comprehensive baseline assessments including 3-night polysomnography, actigraphy for 2 weeks, amyloid-PET and tau-PET imaging, lumbar puncture for CSF biomarkers (Aβ42/40, p-tau181, p-tau217), and neuropsychological battery. Phase 2 (Months 7-12): Stratify participants by sleep disruption severity using sleep efficiency <85% and slow-wave sleep <15% as cutoffs. Randomize 150 participants with significant sleep disruption to intervention arms: CBT-I (n=50), CPAP therapy for those with AHI>15 (n=50), or low-dose trazodone 50mg (n=50). Control group (n=150) receives sleep hygiene education. Phase 3 (Months 13-24): Implement interventions with monthly compliance monitoring. Repeat polysomnography at 6 and 12 months post-intervention. Conduct interim CSF sampling at 12 months. Phase 4 (Months 25-36): Final comprehensive assessment battery identical to baseline. Primary endpoints include changes in amyloid-PET SUVR, CSF p-tau levels, and cognitive composite scores. Secondary measures include sleep architecture parameters, inflammatory markers (IL-6, TNF-α), and brain volume changes via MRI. Statistical analysis uses mixed-effects models controlling for age, APOE4 status, and baseline cognition, with 80% power to detect 20% reduction in biomarker progression.
Expected Outcomes
Participants with baseline sleep efficiency <80% will show 1.5-2.0 fold higher amyloid accumulation rates compared to good sleepers (SUVR increase >0.05 annually vs <0.03, p<0.01)
Sleep interventions will reduce CSF p-tau181 levels by 15-25% compared to controls over 24 months, with CBT-I showing superior efficacy (p<0.05)
Improved slow-wave sleep duration (>20% increase) will correlate with preserved cognitive performance on episodic memory tasks (r=0.4, p<0.001)
Sleep disruption severity at baseline will predict tau-PET accumulation in medial temporal lobe regions with effect size d=0
...
Participants with baseline sleep efficiency <80% will show 1.5-2.0 fold higher amyloid accumulation rates compared to good sleepers (SUVR increase >0.05 annually vs <0.03, p<0.01)
Sleep interventions will reduce CSF p-tau181 levels by 15-25% compared to controls over 24 months, with CBT-I showing superior efficacy (p<0.05)
Improved slow-wave sleep duration (>20% increase) will correlate with preserved cognitive performance on episodic memory tasks (r=0.4, p<0.001)
Sleep disruption severity at baseline will predict tau-PET accumulation in medial temporal lobe regions with effect size d=0.6-0.8
Intervention group will demonstrate 30% slower decline on cognitive composite scores compared to controls (Cohen's d=0.5)
CSF inflammatory markers will decrease by 20-30% in successful sleep intervention responders, mediating cognitive protection effects
Success Criteria
• Demonstrate statistically significant association between baseline sleep disruption and accelerated AD biomarker progression (amyloid or tau, p<0.01)
• Achieve ≥20% reduction in rate of biomarker accumulation in at least one intervention arm compared to controls
• Show dose-response relationship between sleep improvement magnitude and biomarker/cognitive outcomes (correlation r>0.3, p<0.05)
• Document intervention feasibility with ≥80% completion rate and ≥70% adherence to assigned treatments
• Identify sleep metrics that predict future cognitive decline with area under ROC curve >0
...
• Demonstrate statistically significant association between baseline sleep disruption and accelerated AD biomarker progression (amyloid or tau, p<0.01)
• Achieve ≥20% reduction in rate of biomarker accumulation in at least one intervention arm compared to controls
• Show dose-response relationship between sleep improvement magnitude and biomarker/cognitive outcomes (correlation r>0.3, p<0.05)
• Document intervention feasibility with ≥80% completion rate and ≥70% adherence to assigned treatments
• Identify sleep metrics that predict future cognitive decline with area under ROC curve >0.75
• Establish mechanistic pathway linking sleep disruption to AD pathology through inflammatory or clearance mechanisms with effect size d>0.4